


What is claimed is:

1. A composition comprising a fraction isolated or derived from hops and a non-aspirin, non-steroidal anti-inflammatory compound.
2. The composition of claim 1, wherein the fraction isolated or derived from hops is selected from the group consisting of alpha acids, isoalpha acids, reduced isoalpha acids, tetra-hydroisoalpha acids, hexa-hydroisoalpha acids, beta acids, and spent hops.
3. The composition of claim 1, wherein the said fraction isolated or derived from hops comprises a compound of a supragenus having the formula:




wherein R' is selected from the group consisting of carbonyl, hydroxyl, OR, and OCOR, wherein R is alkyl;

wherein R'' is selected from the group consisting of CH(CH₃)₂, CH₂CH(CH₃)₂, and CH(CH₃)CH₂CH₃;

and wherein R, T, X, and Z are independently selected from the group consisting of H, F, Cl, Br, I, and π orbital, with the proviso that if one of R, T, X, or Z is a π orbital, then the adjacent R, T, X, or Z is also a π orbital, thereby forming a double bond.


4. The composition of claim 1, wherein said fraction isolated or derived from hops comprises a compound of Genus A having the formula:



wherein R' is selected from the group consisting of carbonyl, hydroxyl, OR, and OCOR, wherein R is alkyl;

and wherein R'' is selected from the group consisting of CH(CH₃)₂, CH₂CH(CH₃)₂, and CH(CH₃)CH₂CH₃.

5. The composition of claim 1, wherein the fraction isolated or derived from hops comprises a compound of Genus B having the formula:



wherein R' is selected from the group consisting of carbonyl, hydroxyl, OR, and OCOR, wherein R is alkyl;

and wherein R'' is selected from the group consisting of CH(CH₃)₂, CH₂CH(CH₃)₂, and CH(CH₃)CH₂CH₃.

6. The composition of claim 1, wherein said fraction isolated or derived from hops comprises a compound selected from the group consisting of humulone, cohumulone, adhumulone, isohumulone, isocohumulone, isoadhumulone, dihydro-isohumulone, dihydro-isocohumulone, dihydro-adhumulone, tetrahydro-isohumulone, tetrahydro-isocohumulone,

tetrahydro-adhumulone, hexahydro-isohumulone, hexahydro-isocohumulone, and hexahydro-adhumulone.


7. The composition of claim 1, wherein the composition comprises about 0.5 to 10000 mg of said fraction isolated or derived from hops.
8. The composition of claim 7, wherein the composition comprises about 50 to 7500 mg of the fraction isolated or derived from hops.
9. The composition of claim 1, wherein the composition comprises about 0.001 to 10 weight percent of the fraction isolated or derived from hops.
10. The composition of claim 9, wherein the composition comprises about 0.1 to 1 weight percent of the fraction isolated or derived from hops.
11. The composition of claim 1, wherein the non-aspirin, nonsteroidal anti-inflammatory compound is selected from the group consisting of salicylic acid, methyl salicylate, difulunisal, salsalate, olsalazine, sulfasalazine, acetanilide, acetaminophen, phenacetin, mefenamic acid, sodium meclofenamate, tolmetin, ketorolac, diclofenac, ibuprofen, naproxen, sodium daproxen, fenoprofen, ketoprofen, flurbiprofen, oxaprozin, piroxicam, meloxicam, tenoxicam, ampiroxicam, droxicam, pivoxicam, phenylbutazone, oxyphenbutazone, anitpyrine, aminopyrine, dipyrone, celecoxib, rofecoxib, nabumetone, apazone, nimensulide, indomethacin, sulindac, and etodolac.
12. The composition of claim 1, wherein the non-aspirin, nonsteroidal anti-inflammatory comopund is selected from the group consisting of salicylic acid, methyl salicylate, ibuprofen, naproxen, sodium daproxen, fenoprofen, ketoprofen, flurbiprofen, and oxaprozin.
13. The composition of claim 1, wherein the composition further comprises a pharmaceutically acceptable carrier.
14. The composition of claim 1, wherein the composition is formulated for administration orally, topically, parenterally, or rectally.

15. A composition comprising a reduced isoalpha acid isolated from hops and a non-steroidal anti-inflammatory compound.

16. The composition of claim 15, wherein the reduced isoalpha acid is selected from dihydro-isohumulone, dihydro-isocohumulone, and dihydro-adhumulone.

17. A method of producing an analgesic and an anti-ulcerogenic effect in a mammal, comprising administering to the mammal an amount of a fraction isolated or derived from hops sufficient to produce an analgesic and anti-ulcerogenic effect and a nonsteroidal anti-inflammatory compound, whereby administration of said fraction isolated or derived from hops reduces gastric toxicity associated with said non-steroidal anti-inflammatory compound.

18. The method of claim 17, wherein the said fraction isolated or derived from hops comprises a compound of a supragenus having the formula:




wherein R' is selected from the group consisting of carbonyl, hydroxyl, OR, and OCOR, wherein R is alkyl;

wherein R'' is selected from the group consisting of CH(CH₃)₂, CH₂CH(CH₃)₂, and CH(CH₃)CH₂CH₃;

and wherein R, T, X, and Z are independently selected from the group consisting of H, F, Cl, Br, I, and π orbital, with the proviso that if one of R, T, X, or Z is a π orbital, then the adjacent R, T, X, or Z is also a π orbital, thereby forming a double bond.


19. The method of claim 17, wherein said fraction isolated or derived from hops comprises a compound of Genus A having the formula:



wherein R' is selected from the group consisting of carbonyl, hydroxyl, OR, and OCOR, wherein R is alkyl;

and wherein R'' is selected from the group consisting of CH(CH₃)₂, CH₂CH(CH₃)₂, and CH(CH₃)CH₂CH₃.

20. The method of claim 17, wherein the fraction isolated or derived from hops comprises a compound of Genus B having the formula:



wherein R' is selected from the group consisting of carbonyl, hydroxyl, OR, and OCOR, wherein R is alkyl;

and wherein R'' is selected from the group consisting of CH(CH₃)₂, CH₂CH(CH₃)₂, and CH(CH₃)CH₂CH₃.

21. The method of claim 17, wherein said fraction isolated or derived from hops comprises a compound selected from the group consisting of humulone, cohumulone, adhumulone, isohumulone, isocohumulone, isoadhumulone, dihydro-isohumulone, dihydro-isocohumulone, dihydro-adhumulone, tetrahydro-isohumulone, tetrahydro-isocohumulone,

tetrahydro-adhumulone, hexahydro-isohumulone, hexahydro-isocohumulone, and hexahydro-adhumulone.

22. The method of claim 17, wherein the composition comprises about 0.5 to 10000 mg of said fraction isolated or derived from hops.
23. The method of claim 22, wherein the composition comprises about 50 to 7500 mg of the hops derivative.
24. The method of claim 17, wherein the composition comprises about 0.001 to 10 weight percent of the hops derivative.
25. The method of claim 24, wherein the composition comprises about 0.1 to 1 weight percent of the hops derivative.
26. The method of claim 17, wherein the nonsteroidal anti-inflammatory compound is selected from the group consisting of salicylic acid, methyl salicylate, difulunisal, salsalate, olsalazine, sulfasalazine, acetanilide, acetaminophen, phenacetin; mefenamic acid, sodium meclofenamate, tolmetin, ketorolac, diclofenac; ibuprofen, naproxen, sodium daproxen, fenoprofen, ketoprofen, flurbiprofen, oxaprozin, piroxicam, meloxicam, tenoxicam, ampiroxicam, droxicam, pivoxicam, phenylbutazone, oxyphenbutazone, anitpyrine, aminopyrine, dipyrone; celecoxib, rofecoxib; nabumetone; apazone; nimensulide; indomethacin; sulindac; and etodolac.
27. The method of claim 26, wherein the nonsteroidal anti-inflammatory compound is selected from the group consisting of salicylic acid, methyl salicylate, ibuprofen, naproxen, sodium daproxen, fenoprofen, ketoprofen, flurbiprofen, and oxaprozin.
28. The method of claim 17, wherein the composition further comprises a pharmaceutically acceptable carrier.
29. The method of claim 17, wherein the composition is administered orally, topically, parenterally, or rectally.

30. The method of claim 17, wherein fraction isolated or derived from hops is administered concomitantly with said non-steroidal anti-inflammatory compound.
31. The method of claim 17, wherein said fraction isolated or derived from hops is administered after the administration of said non-steroidal anti-inflammatory compound.
32. The method of claim 17, wherein said fraction isolated or derived from hops is administered before the administration of said non-steroidal anti-inflammatory compound.
33. A method of reducing gastric toxicity associated with a non-steroidal anti-inflammatory compound, comprising administering a fraction isolated or derived from hops to an individual being treated with a non-steroidal anti-inflammatory compound.
34. A method of reducing gastroenteropathy, comprising administering a fraction isolated or derived from hops to an individual exhibiting a sign or symptom associated with gastroenteropathy
35. The method of claim 34, wherein said gastroenteropathy involves ulceration.
36. The method of claim 35, wherein said ulceration is induced food, an herb, bacteria, fungi or a drug.